NanoVibronix

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. It targets wound healing and pain therapy, and can be administered at home, without the assistance of medical professionals. The firm's products include WoundShield, PainShield, and UroShield. It operates through the following geographical segments: United States, Israel, Europe, India, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Elmsford, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a Healthcare device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced the company has completed the application process with the Centers for Medicare and Medicaid (CMS) to receive a reimbursement code for its UroShield and PainShield Plus devices. Brian Murphy, Chief Executive Officer of NanoVibronix Inc., commented, "We took the first oppo

NanoVibronix Applies for CMS Reimbursement Code for UroShield® and PainShield Plus®

The stock price of NanoVibronix Inc (NASDAQ: NAOV) increased 26.18% yesterday. This is why it happened.

NAOV Stock Increased 26.18%: Why It Happened

NanoVibronix, Inc. (NASDAQ: NAOV) shares are trading higher after the company announced it received registration approval for UroShield from TGA Australia. 'In addition, the Company also announced that it has signed an agreement with DukeHill Healthcare Pty to distribute the Company's UroShield and PainShield technologies in Australia,' said in the company's press release.

Why Is NanoVibronix's Stock Surging Today?

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a Healthcare device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the Therapeutic Goods Administration (TGA), The Australian Regulatory body for Therapeutic Devices, has granted approval for its UroShield to be used by patients in Australia. In addition, the Company also announced that it has signed an agreement with DukeHill Healt

NanoVibronix Receives Registration Approval for UroShield From TGA Australia

The stock price of NanoVibronix Inc (NASDAQ: NAOV) increased by 133.78% this past week. This is why it happened.

NAOV Stock Increased 133.78% This Past Week: Why It Happened

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices, today announced it has fulfilled the first order of its next generation pain management device, PainShield Plus®, and expects to recognize revenue for the sale in the third quarter of 2021. PainShield Plus covers two times the surface area for pain therapy and is sold at a higher gross ma

NanoVibronix Ships First Order of PainShield Plus

The stock price of NanoVibronix Inc (NASDAQ: NAOV) increased by over 40% pre-market. This is why it happened.

NAOV Stock Increases Over 40% Pre-Market: Why It Happened

The stock price of NanoVibronix Inc (NASDAQ: NAOV) closed 250% higher at $2.61 in very volatile and active afternoon trading Friday, and the stock is up almost 31% at $3.41 during the premarket on Monday. Investors appear to be reacting after the Company announced on Thursday that The Journal of Medical & Surgical Urology is publishing an article with overwhelmingly positive findings from a study of patients that used its UroShield in real-world settings.

Why NanoVibronix (NAOV) Stock Is Trading Higher Monday?

The stock price of NanoVibronix Inc (NASDAQ: NAOV) increased 248.14% today. This is why it happened.

NAOV Stock Increased 248.14%: Why It Happened

Shares of NanoVibronix Inc. more than tripled in very volatile and active afternoon trading Friday, after the company pointed out an upbeat report regarding its treatment for urinary tract infections. The stock was up 204% before the latest volatility trading halt, as volume of 58.8 million shares compared with the full-day average of about 204,000 shares.

NanoVibronix stock triples in very active trading after upbeat report on UTI treatment

Real World Evidence Confirms Effectiveness and Ease of Use of UroShield Real World Evidence Confirms Effectiveness and Ease of Use of UroShield

NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical & Surgical Urology

PainShield Added to DME Schedule for Reimbursement as a Device, Enhances Providers' Ability to Dispense PainShield, Significantly Expands Addressable Market PainShield Added to DME Schedule for Reimbursement as a Device, Enhances Providers' Ability to Dispense PainShield, Significantly Expands Addressable Market

NanoVibronix Announces Expanded CMS Reimbursement Approval for PainShield

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that an independent, real world patient study of its UroShield has commenced at Southampton University Health Sciences in partnership with Southern Health NHS Foundation Trust, an NHS health service provider of community services in the United Kingdom. “This is

NanoVibronix Announces Start of Real World Patient Study of UroShield

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield urology therapy device has been added to the Federal Supply Schedule through a service disabled veteran organization, thus making it easier for Veterans being treated by the Veterans Administration to secure and utilize the UroShield. On Septe

NanoVibronix UroShield Joins PainShield on Federal Supply Schedule, Expanding Access to VA Market

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has received documentation from the National Institute for Health and Care Excellence (NICE) that outlines the timeline for NICE's review and recommendation of the company's UroShield device. Publication of the approval schedule and timeline more clearly

NanoVibronix Reports Schedule Published by NICE for Review of UroShield® Device

NanoVibronix (NAOV) stock is soaring higher on Friday after releasing a filing with the U.S. Securities and Exchange Commission (SEC). The post NAOV Stock: 7 Things to Know About Medical Device Company NanoVibronix appeared first on InvestorPlace.

NAOV Stock: 7 Things to Know About Medical Device Company NanoVibronix

The stock price of NanoVibronix Inc (NASDAQ: NAOV) has increased over 13% pre-market today. This is why it happened.

NAOV Stock Price Increases Over 13% Pre-Market Today: Why It Happened

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has expanded and replaced its original distribution agreement with Ultra Pain Products, Inc. (“UPPI”). Under the terms of the new agreement, which extend the term and increase minimum purchase requirements, UPPI will be the exclusive distributor of priv

NanoVibronix Amends and Expands Distribution Agreement for Its PainShield® and PainShield Plus®

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield and PainShield meet the New Zealand Medical Devices Safety Authority regulatory requirements and have been added to the official WAND database in accordance with the Regulations. Coupled with this approval, the company signed an agreement, and fulfilled its

NanoVibronix Announces UroShield and PainShield Meet New Zealand Medicines and Medical Devices Safety Authority Regulatory Requirements

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced the closing of its previously announced private placement of 8,571,429 shares of common stock (or common stock equivalents) at a purchase price of $0.70 per share that was priced “at-the-market” under Nasdaq Rules and resulted in gross proceeds of approximately

NanoVibronix Announces Closing of $6.0 Million Private Placement Priced At-the-Market

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise $6.0 million through the issuance of 8,571,429 shares of its common stock (or common stock equivalents) at a purchase price of $0.70 per share i

NanoVibronix Announces $6.0 Million Private Placement

A NanoVibronix (NAOV) alert for investors is in order Wednesday as the medical device company's stock is skyrocketing higher. The post NanoVibronix Alert: Why NAOV Stock Is Skyrocketing 133% Today appeared first on InvestorPlace.

NanoVibronix Alert: Why NAOV Stock Is Skyrocketing 133% Today

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced positive findings from an independent evaluation of its UroShield® device on patients who have used the device for up to two years. The results have been submitted to the National Institute for Health and Care Excellence (NICE) for review and consideration. “Fi

Independent Study Finds Significant Benefits Provided by NanoVibronix's UroShield® Device

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today reported its financial results for the quarter ended September 30, 2020 and provided a business update. Financial and Business Highlights Revenue increased 49% to $150,000 Expanded offerings with introduction of PainShield Plus Received U.S. Food and Drug Administration

NanoVibronix Reports Third Quarter 2020 Financial Results, Provides Business Update

ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced the launch of the next generation of its ultrasound pain management device, PainShield Plus® for the treatment of multiple areas of pain in tandem. Brian Murphy, CEO of NanoVibronix, stated, “The introduction of PainShield Plus is a natural extension of our hig

News for NanoVibronix Stock (NAOV)